Drug-induced linear IgA bullous dermatosis after vancomycin discontinuance in a patient with renal insufficiency

Klein, Peter A; Callen, Jeffrey P.

doi:10.1016/s0190-9622(00)90102-6

Cited by 56 publications

(51 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Phenytoin has been previously associated with both TEN and LABD [21,33]. Vancomycin and phenytoin have both been reported to induce LABD, but vancomycin being most consistently implicated [2,34]. Vancomycin has also been reported to cause localized LABD confined to the palms at supratherapeutic levels [35].…”

Section: Discussionmentioning

confidence: 99%

Linear IgA Bullous Disease Presenting as Toxic Epidermal Necrolysis: A Case Report and Review of the Literature

Kakar

Paugh

Jaworsky³

2013

Dermatology

View full text Add to dashboard Cite

A 91-year-old female presented with widespread skin sloughing and bullae clinically mimicking toxic epidermal necrolysis (TEN). The patient was on multiple antibiotics, including vancomycin and piperacillin/tazobactam. Histopathology and direct immunofluorescence were consistent with a diagnosis of linear IgA bullous disease (LABD). In a PubMed review of the literature from 1975 to the present, there have been 15 cases of LABD presenting as TEN clinically and with characteristic linear IgA deposits on direct immunofluorescence studies. Vancomycin and phenytoin were the most commonly implicated medications. Twelve patients saw a resolution or healing of skin lesions after discontinuation of the implicated medication. There were, however, 5 patients who died of complications related to their comorbidities. It is important to include LABD in the differential diagnosis when evaluating patients who clinically present with TEN.

show abstract

Section: Discussionmentioning

confidence: 99%

Linear IgA Bullous Disease Presenting as Toxic Epidermal Necrolysis: A Case Report and Review of the Literature

Kakar

Paugh

Jaworsky³

2013

Dermatology

View full text Add to dashboard Cite

show abstract

“…Various medications have been suspected as potential triggers. The majority of reports implicate vancomycin as the causal agent, with a time lag between onset of therapy and occurrence of the first visible skin lesions of 24 h to 15 days [3,4,11]. Thus far, there is no published case report considering infliximab (IFX) or another tumor necrosis factor-α (TNF-α) inhibitor as the inducing agent of LABD.…”

Section: Introductionmentioning

confidence: 99%

Linear IgA Bullous Dermatosis Secondary to Infliximab Therapy in a Patient with Ulcerative Colitis

Hoffmann

Hadaschik²,

Enk³

et al. 2015

Dermatology

View full text Add to dashboard Cite

Linear IgA bullous disease (LABD) is a rare vesiculobullous autoimmune skin disorder whose etiology and pathogenesis are not completely understood. Its occurrence has been related to malignancies, inflammatory diseases and several drugs. This report describes a 49-year-old Caucasian male with a 14-year history of ulcerative colitis who received infliximab to treat the refractory course of his bowel disease. During induction therapy with infliximab, he developed LABD. Treatment with infliximab was discontinued, and the skin lesions were successfully treated with oral steroids and dapsone. Considering the close chronological relation between administration of the tumor necrosis factor-α inhibitor and onset of the skin disease, we hypothesize that this is the first reported case of infliximab-induced LABD. Similar to psoriasis, it may represent a ‘paradoxical' autoimmune reaction triggered by anti-tumor necrosis factor-α therapy.

show abstract

“…Then triggering event such as: infection and subsequent treatment, may be required to initiate an immunologic response, even in patients who were not previously sensitized to the drug. 6,8,9 In our patient the blistering eruption occurred three weeks after the last dose of the cefuroxime axetil. The disease occurred probably because of two factors -drug and infection together.…”

Section: Figurementioning

confidence: 55%

“…However, in previous report it has been suggested that drug-induced LABD may appear even after the drug discontinuance. 6 However in such cases other clinical conditions (i.e. infection) serving as cofactors may Drug-induced linear IgA bullous dermatosis after discontinuation of cefuroxime axetil treatment, Pastuszczak et al…”

Section: Resultsmentioning

confidence: 99%

“…2 On the other hand, similarly to our patient, there was a case report of drug-induced type of the disease which occurred two weeks after discontinuance of the treatment with the offending drug. 6 The mechanism of drug-induced LABD remains unclear. Two proteins (a 97-kD and a 285-kD) localized in the lamina lucida and sublamina densa have been implicated as potential antigens.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Drug-induced linear IgA bullous dermatosis after discontinuation of cefuroxime axetil treatment

Pastuszczak¹,

Lipko-Godlewska²,

Jaworek³

et al. 2012

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: Linear immunoglobulin A (IgA) bullous dermatosis (LABD) is a rare autoimmune blistering disorder. The disease may be either idiopathic or druginduced. Over the past 30 years, approximately one hundred LABD cases have been described as induced by a wide range of drugs, chiefly antibiotics. Main observations:We report the case of 37-year-old woman who developed pruritic bullous lesions spread all over the body three weeks after her last dose of cefuroxime axetil. Antibiotic therapy was started due to rhino-sinusitis. Conclusions:In most reported cases of drug-induced LABD, skin lesions occur within the time of drug administration. However, the onset of disease may be even after discontinuation of treatment. It seems that in such cases, other clinical conditions (like infection) act, as cofactors of immunologic response. (J Dermatol Case Rep.

show abstract

Drug-induced linear IgA bullous dermatosis after vancomycin discontinuance in a patient with renal insufficiency

Cited by 56 publications

References 30 publications

Linear IgA Bullous Disease Presenting as Toxic Epidermal Necrolysis: A Case Report and Review of the Literature

Linear IgA Bullous Disease Presenting as Toxic Epidermal Necrolysis: A Case Report and Review of the Literature

Linear IgA Bullous Dermatosis Secondary to Infliximab Therapy in a Patient with Ulcerative Colitis

Drug-induced linear IgA bullous dermatosis after discontinuation of cefuroxime axetil treatment

Contact Info

Product

Resources

About